Patent details

EP2776043 Title: BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS

Basic Information

Publication number:
EP2776043
PCT Application Number:
US2012064496
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP128479680
PCT Publication Number:
WO2013071142
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
BIOMARKERS OF RESPONSE TO PROTEASOME INHIBITORS
French Title of Invention:
BIOMARQUEURS DE LA SENSIBILITÉ À DES INHIBITEURS DU PROTÉASOME
German Title of Invention:
BIOMARKER DER REAKTION AUF PROTEASOMENHEMMER
SPC Number:

Dates

Filing date:
09/11/2012
Grant date:
21/02/2018
EP Publication Date:
17/09/2014
PCT Publication Date:
16/05/2013
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
21/02/2018
EP B1 Publication Date:
21/02/2018
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
09/11/2018
Expiration date:
09/11/2032
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
14/02/2018
 
 

Name:
Millennium Pharmaceuticals, Inc.
Address:
40 Landsdowne Street, Cambridge, MA 02139, United States (US)

Inventor

1

Name:
KOENIG, Erik, M.
Address:
United States (US)

2

Name:
BERGER, Allison
Address:
United States (US)

3

Name:
CHATTOPADHYAY, Nibedita
Address:
United States (US)

Priority

1

Priority Number:
201161558474 P
Priority Date:
11/11/2011
Priority Country:
United States (US)

2

Priority Number:
201261721818 P
Priority Date:
02/11/2012
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/69; A61K 38/00; A61P 35/00; C12Q 1/68;

Publication

European Patent Bulletin

Issue number:
201808
Publication date:
21/02/2018
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
30/03/2019 Outgoing Correspondence 1